Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04116437 |
Recruitment Status :
Recruiting
First Posted : October 4, 2019
Last Update Posted : April 25, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Waldenstrom Macroglobulinemia | Drug: Zanubrutinib | Phase 2 |
Expanded Access : An investigational treatment associated with this study is no longer available outside the clinical trial. More info ...
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 90 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib |
Actual Study Start Date : | October 15, 2019 |
Estimated Primary Completion Date : | October 2025 |
Estimated Study Completion Date : | October 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Zanubrutinib
Cohort 1: Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) previously treated with ibrutinib Cohort 2: Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) previously treated with acalabrutinib alone/with ibrutinib |
Drug: Zanubrutinib
Zanubrutinib (BGB-3111) will be orally administered at a dose of 160 mg twice daily or 320mg once daily until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination.
Other Names:
|
- Recurrence and change in severity of treatment-emergent Adverse Events (AEs) of interest. [ Time Frame: 24 months ]
- Overall response as determined by investigator [ Time Frame: 24 months ]
- Progression free survival (PFS) as determined by investigator [ Time Frame: 24 months ]
- Patient reported outcomes as measured by EuroQol five dimension scale (EQ-5D) [ Time Frame: 24 months ]
- Patient reported outcomes as measured by European Organisation for Research and Treatment of Cancer (EORTC) [ Time Frame: 24 months ]
- Disease control rate as determined by investigator [ Time Frame: 24 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Participants must meet protocol defined disease criteria requiring treatment for their respective disease prior to initiation of ibrutinib or acalabrutinib
-
Ibrutinib and acalabrutinib intolerance is defined as an unacceptable toxicity where, in the opinion of the investigator, treatment should be discontinued in spite of optimal supportive care as a result of one of the following:
-
For ibrutinib and acalabrutinib intolerance events:
- 1 or more ≥ Grade 2 nonhematologic toxicities for >7 days (with or without treatment)
- 1 or more ≥ Grade 3 nonhematologic toxicity of any duration
- 1 or more Grade 3 neutropenia with infection or fever of any duration; or
- Grade 4 heme toxicity which persists to the point that the investigator chose to stop therapy due to toxicity NOT progression.
-
For acalabrutinib intolerance events only;
- 1 or more ≥ Grade 1 nonhematologic toxicities of any duration with > 3 recurrent episodes; or
- 1 or more ≥ Grade 1 nonhematologic toxicities for > 7 days (with or without treatment); or
- Inability to use acid-reducing agents or anticoagulants (eg, proton pump inhibitors, warfarin) due to concurrent acalabrutinib use
-
- Ibrutinib and/or acalabrutinib-related ≥ Grade 2 toxicities must have resolved to ≤ Grade 1 or baseline prior to initiating treatment with zanubrutinib. Grade 1 acalabrutinib-related toxicities must have resolved to Grade 0 or baseline prior to initiating treatment with zanubrutinib.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Absolute neutrophil count (ANC) ≥ 1000/mm^3 with or without growth factor support and platelet count ≥ 50,000/mm^3 (may be post-transfusion), on or prior to C1D1 of zanubrutinib
Key Exclusion Criteria:
-
Clinically significant cardiovascular disease including the following:
- Myocardial infarction within 6 months before the Screening
- Unstable angina within 3 months before the Screening
- New York Heart Association class III or IV congestive heart failure
- History of sustained ventricular tachycardia, ventricular fibrillation, and/or Torsades de Pointes
- QT interval corrected by Fridericia's formula > 480 milliseconds
- History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place
- History of central nervous system (CNS) hemorrhage
- Documented progressive disease (PD) during ibrutinib and/or acalabrutinib treatment.
- Have received any anticancer therapy (other than immunotherapy) for CLL/SLL, WM, MCL, and MZL < 7 days before any Screening assessments are performed or any immunotherapy treatment, taken alone or as part of a chemoimmunotherapy regimen, < 4 weeks before any Screening assessments are performed
- Requires ongoing need for corticosteroid treatment > 10 mg daily of prednisone or equivalent corticosteroid. Note: Systemic corticosteroids must be fully tapered off/discontinued ≥ 5 days before the first dose of study drug is administered.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04116437
Contact: BeiGene | 1-877-828-5568 | clinicaltrials@beigene.com |
Responsible Party: | BeiGene |
ClinicalTrials.gov Identifier: | NCT04116437 |
Other Study ID Numbers: |
BGB-3111-215 |
First Posted: | October 4, 2019 Key Record Dates |
Last Update Posted: | April 25, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
BGB-3111 Zanubrutinib Ibrutinib Intolerance BTK Inhibitor Acalabrutinib Intolerance |
Lymphoma Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Mantle-Cell Waldenstrom Macroglobulinemia Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin Leukemia, Lymphoid Leukemia Hematologic Diseases Leukemia, B-Cell |
Chronic Disease Disease Attributes Pathologic Processes Neoplasms, Plasma Cell Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hemorrhagic Disorders Zanubrutinib Tyrosine Kinase Inhibitors Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |